{"doi":"10.1093/ndt/gfv215","title":"Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?","abstract":null,"journal":"Nephrology Dialysis Transplantation","year":2015,"id":17004,"datarank":0.34176939057192457,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.13382523640394092,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.13382523640394092,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":3,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":123262,"name":"Vladimir Tesar","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"25999373","pmcid":null,"openalex_id":"https://openalex.org/W2265981062","authors":[],"funders":[],"total_grants":0,"fwci":0.551,"citation_percentile":0.74196072,"influential_citations":1,"citation_trend":[{"year":2016,"count":2},{"year":2023,"count":1}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://academic.oup.com/ndt/article-pdf/30/7/1088/6839210/gfv215.pdf","host_type":"journal"},{"url":"https://academic.oup.com/ndt/article-pdf/30/7/1088/6839210/gfv215.pdf","host_type":"BRONZE"},{"url":"https://academic.oup.com/ndt/article-pdf/30/7/1088/6839210/gfv215.pdf","host_type":"publisher"},{"url":"http://academic.oup.com/ndt/article-pdf/30/7/1088/6839210/gfv215.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/ndt/gfv215","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/25999373","host_type":"repository"}],"fields_of_study":["Vasculitis and related conditions","Otitis Media and Relapsing Polychondritis","Sarcoidosis and Beryllium Toxicity Research","Medicine","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","Antibodies, Monoclonal, Murine-Derived","Clinical Trials as Topic","Humans","Immunologic Factors","Prognosis","Remission Induction","Rituximab"],"mesh_terms":["Rituximab","Clinical Trials as Topic","Humans","Immunologic Factors","Prognosis","Remission Induction","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","Antibodies, Monoclonal, Murine-Derived"],"keywords":["Rituximab","Medicine","Vasculitis","Cyclophosphamide","ANCA-Associated Vasculitis","Immunology","Internal medicine","Lymphoma","Disease","Chemotherapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-02T15:45:39.790947Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}